Abstract
Abstract Estrogen, an immunomodulator, is believed to be involved in many autoimmune inflammatory conditions. We reported that estrogen treatment of C57BL/6 mice favors the induction of Th1 responses such as secretion of IFNγ. However, the mechanisms involved in response to IFNγ are not well known. Therefore, we investigated the molecular pathways in splenocytes from estrogen-treated mice following in vitro exposure to Th1(IFNγ)-inducing cytokines: IFNγ, IL12 and IL27. ConA activated splenocytes from estrogen treated mice induced an IFNγ-dependent-increase in iNOS, nitric oxide, COX2 and MCP1. In vitro addition of IFNγto ConA activated splenocytes from IFNγ −/− mice induced iNOS and MCP1 primarily in estrogen-treated mice. Since IFNγ is a potent inducer of IRF1, interestingly that neither direct addition of IFNγ to splenocytes from wildtype or IFNγ −/− mice nor the addition of IFNγ to T cells, induced IRF1 in cells from estrogen-treated mice. Activated splenocytes from estrogen-treated mice had noticeably increased levels of the IFNγ-specific transcription factor T-bet, although there were no marked changes in phosphorylated STAT1. Estrogen-induced upregulation of T-bet was largely due to IFNγ and IL27, but not IL12. Thus, these findings contribute novel insight regarding the pro-inflammatory effects of estrogen on the immune system and may lead to novel therapeutic approaches for autoimmune diseases. Supported by NIH grant 5RO1 AI51880.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.